Chordomas are rare bone tumors that arise from notochord remnants. They most commonly occur in the sacrum, but they also can be seen in the skull base, cervical spine, and thoracolumbar vertebrae. Chordomas account for 1 to 4% of all primary skeletal tumors. They are usually indolent, locally growing tumors. Distant metastasis has been reported in 3 to 48% of cases. When metastasis occurs, it is usually observed in the lung, bone, and liver. To the best of our knowledge, no case of a chordoma metastasis to the tongue has been previously reported in the literature. We report such a case in a 61-yearold man.
Introduction
Chordomas are low-grade malignant tumors that derive from the remnants of the notochord. Their annual incidence is 0.1 to 0.8 for every 1 million population. 1 Their rarity notwithstanding, they are the most common primary malignancies of the vertebrae.
Chordomas generally arise within the sacrococcygeal area (50% of cases); they are less often seen in the skull base (35%) and vertebrae (15%). 2 Although chordomas occur in patients of all ages, they are most often seen in adults, as the incidence peaks during the fourth decade of life. 1 These tumors occur twice as often in males as in females. 3 The clinical presentation of chordomas is mostly related to the mass effect, which may produce pain. 3 Chordomas have been reported to metastasize to distant sites in 3 to 48% of cases. 4 Distant metastases generally involve the lung, liver, and lymph nodes. 4 To the best of our knowledge, no case of a metastasis to the tongue has been previously reported. We now report the first such case.
Case report
A 61-year-old man was referred to our clinic for evaluation of a tongue lesion. His medical history indicated that he had previously undergone wide surgical excision of a sacral chordoma. He subsequently underwent 6 sessions of curative chemotherapy and 10 sessions of curative radiotherapy for treatment of residual tumor. At the 6-month follow-up, a sacral recurrence had been observed radiologically. In the subsequent operation, the tumor could not be completely excised, and again, residual tumor had to be left. Pharmacotherapy was started with imatinib at 800 mg once daily. However, after 1 year of treatment, positron emission tomography/ computed tomography (PET/CT) revealed the presence of multiple metastatic lesions in the right lung lobe (6 cm in diameter), gluteal area, right proximal femur, posterior left humerus, posterior right scapula, inferior right scalene muscle, and the intercostal muscles adjacent to the fifth rib. PET/CT demonstrated no uptake in the tongue.
Twenty days later, the patient was admitted to our clinic for evaluation of a growing, painless, well-demarcated, round tongue lesion. Physical examination identified a 2 × 1-cm mass on the tongue, close to the midline and just in front of the circumvallate papillae ( figure 1, A) . The mass was solid on palpation, and it resembled a malignant metastasis without deep invasion. Also, a sliding 3-cm nodular lesion was palpated in the patient's right thyroid area during swallowing. Findings on otoscopic, anterior rhinoscopic, and nasopharyngeal examinations were normal.
The tongue lesion was widely excised with 1.5-cm surgical margins ( figure 1, B) . Neck dissection was not BISKIN, ERDEMIR, ELIÇORA, AYDINLI, ÖZDAMAR preferred because the metastatic lymphadenopathies were believed to have had a sacral and/or lung origin rather than a lingual origin. Microscopic analysis identified the tumor as a metastatic chordoma (figure 2). Fine-needle aspiration biopsy was performed on the thyroid lesion and it was pathologically benign.
Postoperatively, because tumor progression was seen after radiotherapy with imatinib, a tyrosine kinase inhibitor (pazopanib at 800 mg/day once daily) was started. The lingual tumor in our patient had not recurred at 1 year of follow-up.
Discussion
Consistent with most reports of chordoma in the literature, our patient was male 3 and his primary tumor was in the sacrococcygeal area. 2 PET/CT for the evaluation of distant metastases found metastatic lesions in the lung, gluteal muscles, femur, humerus, scapula, scalene muscle and intercostal muscle. An interesting aspect of this case is that our patient developed multiple muscle metastases.
Twenty days after PET/CT found no tumor in our patient's tongue, the appearance of a 2 × 1-cm mass on the top of the tongue illustrates the rapidity with which chordomas can grow. Even so, progression in this case occurred much more rapidly than what has generally been reported in the literature. Also, the smooth, filmy outline of the tongue mass on the macroscopic view and its midline location differ from the characteristics of other tongue tumors. Primary tongue tumors are generally located on the lateral side, which is most often exposed to trauma. 5 They usually exhibit a rough outline, and squamous cell carcinoma is the most common type. 5 While surgery is the first-line treatment for chordomas, total excision is rarely successful, and the local recurrence rate has been reported to be as high as 95%. 3, 6 If a tumor cannot be totally excised because a wide surgical area cannot be secured, high-dose radiotherapy or radiochemotherapy can be administered. 7 Even so, the reported 5-year survival rate is only 50%. 2 At our patient's first surgery, wide excision was performed, but tumor recurrence was noted in 6 months. In the subsequent operation, the tumor could not be completely excised, and residual tumor had to be left.
Despite the high local recurrence rate of chordomas, wide resection of the tongue tumor with a 1.5-cm surgical margin was adequate in this case. Because metastasis of a chordoma to the tongue has not been previously reported in the literature, no data are available on recurrence rates. One year of follow-up of our patient revealed no residual tumor or recurrence. Thus, we conclude that surgical excision is a suitable treatment for metastatic chordomas. Neck dissection was not preferred because the metastatic lymphadenopathies were believed to have had a sacral and/or lung origin rather than a tongue origin.
Target treatments have been used for chordomas in recent years. The goal of these treatments is to prevent tumor progression by inhibiting the molecular mechanisms. For this reason, inhibitors of epidermal growth factor and platelet-derived growth factor (PDGF), both of which are tyrosine kinase inhibitors, are generally METASTATIC CHORDOMA OF THE TONGUE: CASE REPORT used. 8 Our patient had undergone postoperative radiotherapy 3 years before being seen at our facility. Because tumor progression was seen after radiotherapy with imatinib, a tyrosine kinase inhibitor was started. Imatinib is a PDGF-β inhibitor. Our patient's sacral recurrence had progressed and metastasized although he had taken imatinib at 800 mg/day for 1 year. After the lingual metastasis had developed, he was switched to pazopanib at 800 mg once daily.
This case represents a new experience in the diagnosis and treatment of a chordoma metastatic to the tongue.
